JP6316591B2 - 光線療法用のエネルギー印加された眼科用装置を形成するための装置及び方法 - Google Patents
光線療法用のエネルギー印加された眼科用装置を形成するための装置及び方法 Download PDFInfo
- Publication number
- JP6316591B2 JP6316591B2 JP2013552634A JP2013552634A JP6316591B2 JP 6316591 B2 JP6316591 B2 JP 6316591B2 JP 2013552634 A JP2013552634 A JP 2013552634A JP 2013552634 A JP2013552634 A JP 2013552634A JP 6316591 B2 JP6316591 B2 JP 6316591B2
- Authority
- JP
- Japan
- Prior art keywords
- light
- light source
- lens
- energy source
- energy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 77
- 238000001126 phototherapy Methods 0.000 title description 45
- 239000000203 mixture Substances 0.000 claims description 39
- 239000000178 monomer Substances 0.000 claims description 32
- 239000010409 thin film Substances 0.000 claims description 21
- 239000000758 substrate Substances 0.000 claims description 20
- 238000004891 communication Methods 0.000 claims description 19
- 230000000007 visual effect Effects 0.000 claims description 15
- 238000000149 argon plasma sintering Methods 0.000 claims description 10
- 229910001416 lithium ion Inorganic materials 0.000 claims description 9
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 claims description 7
- 239000006185 dispersion Substances 0.000 claims description 7
- 238000005286 illumination Methods 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 6
- 210000004087 cornea Anatomy 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 230000004888 barrier function Effects 0.000 claims description 4
- 230000004438 eyesight Effects 0.000 claims description 4
- 238000000151 deposition Methods 0.000 claims description 2
- GELKBWJHTRAYNV-UHFFFAOYSA-K lithium iron phosphate Chemical compound [Li+].[Fe+2].[O-]P([O-])([O-])=O GELKBWJHTRAYNV-UHFFFAOYSA-K 0.000 claims description 2
- 239000013307 optical fiber Substances 0.000 claims description 2
- 239000011343 solid material Substances 0.000 claims description 2
- 230000005055 memory storage Effects 0.000 claims 1
- 210000000695 crystalline len Anatomy 0.000 description 187
- 229920000642 polymer Polymers 0.000 description 53
- 239000000463 material Substances 0.000 description 39
- 239000002904 solvent Substances 0.000 description 28
- -1 photoinitiators Substances 0.000 description 27
- 229920001296 polysiloxane Polymers 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 17
- 239000000049 pigment Substances 0.000 description 17
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 238000000465 moulding Methods 0.000 description 16
- 238000013461 design Methods 0.000 description 15
- 239000003990 capacitor Substances 0.000 description 13
- 230000003287 optical effect Effects 0.000 description 13
- 238000006116 polymerization reaction Methods 0.000 description 13
- 238000000576 coating method Methods 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 208000012672 seasonal affective disease Diseases 0.000 description 12
- 239000000017 hydrogel Substances 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 239000000654 additive Substances 0.000 description 9
- 229920001577 copolymer Polymers 0.000 description 9
- 102100026735 Coagulation factor VIII Human genes 0.000 description 8
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 8
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 8
- 239000003086 colorant Substances 0.000 description 8
- 239000003999 initiator Substances 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 238000009835 boiling Methods 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000012937 correction Methods 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 239000000446 fuel Substances 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 description 4
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical group NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000005611 electricity Effects 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 4
- 229960003987 melatonin Drugs 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 229920000098 polyolefin Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- KIWATKANDHUUOB-UHFFFAOYSA-N propan-2-yl 2-hydroxypropanoate Chemical compound CC(C)OC(=O)C(C)O KIWATKANDHUUOB-UHFFFAOYSA-N 0.000 description 4
- 239000004065 semiconductor Substances 0.000 description 4
- 229920002554 vinyl polymer Chemical group 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000010406 cathode material Substances 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 239000012778 molding material Substances 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- VAYTZRYEBVHVLE-UHFFFAOYSA-N 1,3-dioxol-2-one Chemical compound O=C1OC=CO1 VAYTZRYEBVHVLE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000005058 Isophorone diisocyanate Substances 0.000 description 2
- 241001124569 Lycaenidae Species 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229910018557 Si O Inorganic materials 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000005157 alkyl carboxy group Chemical group 0.000 description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007600 charging Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 2
- 125000005442 diisocyanate group Chemical group 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000004146 energy storage Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical group NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
- 239000001023 inorganic pigment Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 description 2
- QYPPRTNMGCREIM-UHFFFAOYSA-N methylarsonic acid Chemical compound C[As](O)(O)=O QYPPRTNMGCREIM-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012860 organic pigment Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000052 poly(p-xylylene) Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 238000010526 radical polymerization reaction Methods 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Inorganic materials [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 125000005504 styryl group Chemical group 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004381 surface treatment Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012876 topography Methods 0.000 description 2
- LVLANIHJQRZTPY-UHFFFAOYSA-N vinyl carbamate Chemical compound NC(=O)OC=C LVLANIHJQRZTPY-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2,2'-azo-bis-isobutyronitrile Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
- NWBTXZPDTSKZJU-UHFFFAOYSA-N 3-[dimethyl(trimethylsilyloxy)silyl]propyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC[Si](C)(C)O[Si](C)(C)C NWBTXZPDTSKZJU-UHFFFAOYSA-N 0.000 description 1
- HBOYQHJSMXAOKY-UHFFFAOYSA-N 3-[methyl-bis(trimethylsilyloxy)silyl]propyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C HBOYQHJSMXAOKY-UHFFFAOYSA-N 0.000 description 1
- JSGVZVOGOQILFM-UHFFFAOYSA-N 3-methoxy-1-butanol Chemical compound COC(C)CCO JSGVZVOGOQILFM-UHFFFAOYSA-N 0.000 description 1
- BESKSSIEODQWBP-UHFFFAOYSA-N 3-tris(trimethylsilyloxy)silylpropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC[Si](O[Si](C)(C)C)(O[Si](C)(C)C)O[Si](C)(C)C BESKSSIEODQWBP-UHFFFAOYSA-N 0.000 description 1
- KLNBFEHQGRIYGL-UHFFFAOYSA-N 4-[[4-ethenoxycarbonyloxybutyl(dimethyl)silyl]oxy-dimethylsilyl]butyl ethenyl carbonate Chemical compound C=COC(=O)OCCCC[Si](C)(C)O[Si](C)(C)CCCCOC(=O)OC=C KLNBFEHQGRIYGL-UHFFFAOYSA-N 0.000 description 1
- CGLVZFOCZLHKOH-UHFFFAOYSA-N 8,18-dichloro-5,15-diethyl-5,15-dihydrodiindolo(3,2-b:3',2'-m)triphenodioxazine Chemical compound CCN1C2=CC=CC=C2C2=C1C=C1OC3=C(Cl)C4=NC(C=C5C6=CC=CC=C6N(C5=C5)CC)=C5OC4=C(Cl)C3=NC1=C2 CGLVZFOCZLHKOH-UHFFFAOYSA-N 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- YPBCOBSGEZTXGS-UHFFFAOYSA-N C[Si](C)(C)CC=COC(=O)O Chemical compound C[Si](C)(C)CC=COC(=O)O YPBCOBSGEZTXGS-UHFFFAOYSA-N 0.000 description 1
- PJMWNILDCBHWSD-UHFFFAOYSA-N C[Si](C)(C)CCC=COC(O)=O Chemical compound C[Si](C)(C)CCC=COC(O)=O PJMWNILDCBHWSD-UHFFFAOYSA-N 0.000 description 1
- 208000017164 Chronobiology disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010018258 Giant papillary conjunctivitis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical group CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001085205 Prenanthella exigua Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- PKDAKIZIHVXQTQ-UHFFFAOYSA-N [2-hydroxy-3-[3-tris(trimethylsilyloxy)silylpropoxy]propyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)COCCC[Si](O[Si](C)(C)C)(O[Si](C)(C)C)O[Si](C)(C)C PKDAKIZIHVXQTQ-UHFFFAOYSA-N 0.000 description 1
- NLALDIQYFVAZBM-UHFFFAOYSA-N [2-hydroxy-6-[5-hydroxy-6-(2-methylprop-2-enoyloxy)hexoxy]hexyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CCCCOCCCCC(O)COC(=O)C(C)=C NLALDIQYFVAZBM-UHFFFAOYSA-N 0.000 description 1
- QSNQXZYQEIKDPU-UHFFFAOYSA-N [Li].[Fe] Chemical compound [Li].[Fe] QSNQXZYQEIKDPU-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000010405 anode material Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229940067573 brown iron oxide Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010538 cationic polymerization reaction Methods 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000012986 chain transfer agent Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- XCJYREBRNVKWGJ-UHFFFAOYSA-N copper(II) phthalocyanine Chemical compound [Cu+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 XCJYREBRNVKWGJ-UHFFFAOYSA-N 0.000 description 1
- 238000003851 corona treatment Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 description 1
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004870 electrical engineering Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- FXPHJTKVWZVEGA-UHFFFAOYSA-N ethenyl hydrogen carbonate Chemical compound OC(=O)OC=C FXPHJTKVWZVEGA-UHFFFAOYSA-N 0.000 description 1
- ILHMPZFVDISGNP-UHFFFAOYSA-N ethenyl n-[3-tris(trimethylsilyloxy)silylpropyl]carbamate Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)CCCNC(=O)OC=C ILHMPZFVDISGNP-UHFFFAOYSA-N 0.000 description 1
- IIQWTZQWBGDRQG-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate;isocyanic acid Chemical compound N=C=O.CCOC(=O)C(C)=C IIQWTZQWBGDRQG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000004384 eye physiology Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- LNCPIMCVTKXXOY-UHFFFAOYSA-N hexyl 2-methylprop-2-enoate Chemical compound CCCCCCOC(=O)C(C)=C LNCPIMCVTKXXOY-UHFFFAOYSA-N 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- LDHBWEYLDHLIBQ-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide;hydrate Chemical compound O.[OH-].[O-2].[Fe+3] LDHBWEYLDHLIBQ-UHFFFAOYSA-M 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- 238000003698 laser cutting Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229910000625 lithium cobalt oxide Inorganic materials 0.000 description 1
- 229910002102 lithium manganese oxide Inorganic materials 0.000 description 1
- BFZPBUKRYWOWDV-UHFFFAOYSA-N lithium;oxido(oxo)cobalt Chemical compound [Li+].[O-][Co]=O BFZPBUKRYWOWDV-UHFFFAOYSA-N 0.000 description 1
- VLXXBCXTUVRROQ-UHFFFAOYSA-N lithium;oxido-oxo-(oxomanganiooxy)manganese Chemical compound [Li+].[O-][Mn](=O)O[Mn]=O VLXXBCXTUVRROQ-UHFFFAOYSA-N 0.000 description 1
- 238000010550 living polymerization reaction Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 101150018863 maa gene Proteins 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical group CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- HOZLHJIPBBRFGM-UHFFFAOYSA-N n-dodecyl-2-methylprop-2-enamide Chemical compound CCCCCCCCCCCCNC(=O)C(C)=C HOZLHJIPBBRFGM-UHFFFAOYSA-N 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000013651 non-24-hour sleep-wake syndrome Diseases 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007649 pad printing Methods 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000006233 propoxy propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 125000005373 siloxane group Chemical group [SiH2](O*)* 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- XAASNKQYFKTYTR-UHFFFAOYSA-N tris(trimethylsilyloxy)silicon Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)O[Si](C)(C)C XAASNKQYFKTYTR-UHFFFAOYSA-N 0.000 description 1
- XMDMAACDNUUUHQ-UHFFFAOYSA-N vat orange 1 Chemical compound C1=CC(C2=O)=C3C4=C1C1=CC=CC=C1C(=O)C4=CC=C3C1=C2C(Br)=CC=C1Br XMDMAACDNUUUHQ-UHFFFAOYSA-N 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
- B29D11/00—Producing optical elements, e.g. lenses or prisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0618—Psychological treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
- B29D11/00—Producing optical elements, e.g. lenses or prisms
- B29D11/00009—Production of simple or compound lenses
- B29D11/00038—Production of contact lenses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
- B29D11/00—Producing optical elements, e.g. lenses or prisms
- B29D11/0074—Production of other optical elements not provided for in B29D11/00009- B29D11/0073
- B29D11/00807—Producing lenses combined with electronics, e.g. chips
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C11/00—Non-optical adjuncts; Attachment thereof
- G02C11/04—Illuminating means
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
- A61N2005/0647—Applicators worn by the patient the applicator adapted to be worn on the head
- A61N2005/0648—Applicators worn by the patient the applicator adapted to be worn on the head the light being directed to the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0652—Arrays of diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
- A61N2005/0663—Coloured light
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Mechanical Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Social Psychology (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Child & Adolescent Psychology (AREA)
- Developmental Disabilities (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Eyeglasses (AREA)
- Radiation-Therapy Devices (AREA)
- Materials For Medical Uses (AREA)
- Casting Or Compression Moulding Of Plastics Or The Like (AREA)
Description
本出願は、2011年2月4日に出願された米国特許仮出願第61/439,535号、及び2012年1月31日に出願された米国特許出願第13/362,275号に対する優先権を主張し、これらの内容は依拠され参照により組み込まれる。
本発明は、エネルギー印加された生物医学的装置を製造するための方法及び装置、より具体的には、いくつかの実施形態において、光線療法用のエネルギー印加された眼科用レンズを製造するための方法及び装置を記述するものである。
本発明を対象とする本説明文及び特許請求の範囲においては様々な用語が使用され得るが、これらには以下の定義が適用される。
図1を参照すると、眼科用レンズの代表的な成形100の図がエネルギー源109及び光源109aと共に図示される。本明細書で使用する場合、成形という用語は、レンズ形成混合物の反応又は硬化の際に所望の形状の眼科用レンズが製造されるように、レンズ形成混合物をその中に分配することができる、空洞105を有する単一、又は多部分装置100を含む。本発明の成形及び成形組立品100は、複数の「成形部分」又は「成形片」101〜102から構成される。成形部分101〜102を組み合わせて、空洞105を成形部分101〜102間に形成し、その中にレンズを形成することができるようにすることができる。このような成形部分101〜102の組み合わせは、一時的であることが好ましい。レンズが形成されたら、レンズを取り出すために成形部分101〜102を再び分離することができる。
図2を参照すると、眼科用レンズ201は、エネルギー源202、光源202a、及び構成要素203と共に図示される。
R1は、独立して、一価反応性基、一価アルキル基、又は一価アリール基から選択され、前述のいずれかは、ヒドロキシ、アミノ、オキサ、カルボキシ、アルキルカルボキシ、アルコキシ、アミド、カルバメート、カーボネート、ハロゲン、又はこれらの組み合わせから選択される官能基を更に含み得、1〜100 Si−Oの反復単位を含む一価シロキサン鎖は、アルキル、ヒドロキシ、アミノ、オキサ、カルボキシ、アルキルカルボキシ、アルコキシ、アミド、カルバメート、ハロゲン、又はこれらの組み合わせから選択される官能基を更に含むこともあり、
式中、b=0〜500であり、bが0以外のときに、bは、表示値と同等のモードを有する分配であると理解され、
少なくとも1つのR1は、一価反応性基を含み、一部の実施形態では、1〜3個のR1が一価反応性基を含む。
2−ヒドロキシ−3−メタクリルオキシプロピルオキシプロピル−トリ(トリメチルシロキシ)シラン、
3−メタクリルオキシプロピルトリス(トリメチルシロキシ)シラン(「TRIS」)、
3−メタクリルオキシプロピルビス(トリメチルシロキシ)メチルシラン、及び
3−メタクリルオキシプロピルペンタメチルジシロキサンが含まれる。
Rは、水素又はメチルを意味し、dは1、2、3又は4、そしてqは0又は1である。
式IV〜VI
(*D*A*D*G)a *D*D*E1;
E(*D*G*D*A)a *D*G*D*E1又は
E(*D*A*D*G)a *D*A*D*E1
この場合、Dは、炭素原子6〜30個を有するアルキルジラジカル、アルキルシクロアルキルジラジカル、シクロアルキルジラジカル、アリールジラジカル又はアルキルアリールジラジカルを示し、
Gは、炭素原子1〜40個を有するアルキルジラジカル、シクロアルキルジラジカル、アルキルシクロアルキルジラジカル、アリールジラジカル又はアルキルアリールジラジカルを示し、これは、主鎖中にエーテル、チオ又はアミン結合を含有できる。
*はウレタン又はウレイド結合を意味し、
aは、少なくとも1であり、
Aは次の式の二価重合ラジカルを意味する。
以下の方法ステップは、本発明のいくつかの態様により実施しても良いプロセスの例として与えられる。本方法のステップが示される順番は限定を意図するものではなく、他の順番を用いて本発明を実施しても良いことを理解されるべきである。加えて、本発明を実施するために全てのステップを必要とするわけではなく、また本発明の種々の実施形態には付加的なステップを含んでも良い。
CH3(CH2)x−L−COCHR=CH2
式中、Lは、−NH、又は酸素であってよく、xは2〜24の全ての数であってよく、Rは、
C1〜C6アルキル、又は水素であってよく、好ましくはメチル、又は水素である。そのようなアミド及びエステルの例は、ラウリルメタクリルアミド及びヘキシルメタクリレート樹脂を含むが、これらに限定されない。更に別の実施例として、カルバメート及び尿素を拡大する脂肪族ポリマーを使用して、結合ポリマーを形成し得る。
図3を参照すると、自動装置310が、1つ又は2つ以上の媒体移送境界部311を有するものとして例示される。例示されるように、それぞれ関連づけられている媒体314を備えた多数の成形部分が、パレット313に収容され、媒体移送境界部311に送られる。実施形態は、エネルギー源及び光源を多数の媒体314に個別に定置する単一の境界部311、又はエネルギー源及び光源を多数の媒体、例えば成形部分314に同時に(いくつかの実施形態では各成形に)定置する多数の境界部(図示せず)を含み得る。
上述され、以下の特許請求の範囲によって更に定義される本発明は、光線療法を提供するための光源を有する眼科用レンズを処理する方法、及びかかる方法を実践するための装置、並びにそれによって形成される眼科用レンズを提供する。
(1) 眼科用レンズを形成する方法であって、
第1の成形部分に近接した光源と電気的に導通するエネルギー源を定置することと、
前記第1の成形部分内に反応性モノマー混合物を堆積させることと、
前記反応性モノマー混合物と接触させて前記エネルギー源及び光源を配置することと、
前記第1の成形部分を第2の成形部分に近接して配置し、それによってレンズ空洞内に前記エネルギー源及び光源、並びに反応性モノマー混合物の少なくとも一部を有するレンズ空洞を形成することと、
前記反応性モノマー混合物を化学線に曝露することと、
を含む方法。
(2) 前記光源と電気的に導通している前記エネルギー源が電気化学セルを含む、実施態様1に記載の方法。
(3) 前記エネルギー源が前記光源に十分な電力を提供して、前記光源から光を放射できる、実施態様2に記載の方法。
(4) 前記エネルギー源が物理的に基材に取り付けられ、前記基材が、前記第1の成形部分及び前記第2の成形部分の一方又は両方と接触して定置される、実施態様2に記載の方法。
(5) 前記基材が集積回路を含み、前記方法が前記エネルギー源を前記基材に固定することを追加的に含む、実施態様4に記載の方法。
(7) 前記エネルギー源が薄膜電気化学セルを含む、実施態様1に記載の方法。
(8) 前記電気化学セルがリチウムイオン電池を含む、実施態様7に記載の方法。
(9) 前記電気化学セルが再充電可能な固体材料を含む、実施態様7に記載の方法。
(10) 前記電気化学セルがナノスケール結晶を含むカソードを含む、実施態様7に記載の方法。
(12) 前記光源が450〜500ナノメートルの波長で青色光を放射する、実施態様1に記載の装置。
(13) 前記光源が470〜480ナノメートルの波長で青色光を放射する、実施態様12に記載の装置。
(14) 前記光源が約2,000〜3,000ルクスの光を放射する、実施態様13に記載の装置。
(15) 前記光源が475〜525ナノメートルの波長で緑色光を放射する、実施態様1に記載の装置。
(17) 前記ライトが約300〜400ルクスの光を放射する、実施態様16に記載の装置。
(18) 前記光源が1つ又は2つ以上の発光ダイオードを含む、実施態様1に記載の装置。
(19) 前記装置が1本又は2本以上の光パイプを含む、実施態様18に記載の装置。
(20) 前記1本又は2本以上の光パイプが光ファイバー経路を含む、実施態様19に記載の装置。
Claims (24)
- 眼科用レンズを形成する方法であって、
第1の成形部分に近接して、光源と電気的に導通するエネルギー源を定置することと、
前記第1の成形部分内に反応性モノマー混合物を堆積させることと、
前記反応性モノマー混合物と接触させて前記エネルギー源及び光源を配置することと、
前記第1の成形部分を第2の成形部分に近接して配置し、それによってレンズ空洞内に前記エネルギー源及び光源、並びに反応性モノマー混合物の少なくとも一部を有するレンズ空洞を形成することと、
前記反応性モノマー混合物を化学線に曝露することと、
を含み、
前記エネルギー源及び光源は、前記眼科用レンズの視覚ゾーンの周囲のまわりの環状の領域内に配置されており、
前記光源は、前記眼科用レンズの凹状表面の方向に光を放射するように構成されており、
前記環状の領域は、前記光源から目の角膜上への前記光の分散を生じさせる光散乱領域を含み、
前記光散乱領域は、前記環状の領域内に環を形成し、
前記眼科用レンズは、前記光散乱領域と前記レンズの前記視覚ゾーンの外周との間に内部バリアを含む、方法。 - 前記光源と電気的に導通している前記エネルギー源が電気化学セルを含む、請求項1に記載の方法。
- 前記エネルギー源が前記光源に電力を提供して、前記光源から前記光を放射できる、請求項2に記載の方法。
- 前記エネルギー源が物理的に基材に取り付けられ、前記基材が、前記第1の成形部分及び前記第2の成形部分の一方又は両方と接触して定置される、請求項2に記載の方法。
- 前記基材が集積回路を含み、前記方法が前記エネルギー源を前記基材に固定することを追加的に含む、請求項4に記載の方法。
- 前記基材が多数の異なる部分を含む、請求項5に記載の方法。
- 前記エネルギー源が薄膜電気化学セルを含む、請求項1に記載の方法。
- 前記電気化学セルがリチウムイオン電池を含む、請求項7に記載の方法。
- 前記電気化学セルが再充電可能な固体材料を含む、請求項7に記載の方法。
- 前記電気化学セルがナノスケール結晶を含むカソードを含む、請求項7に記載の方法。
- 前記ナノスケール結晶がリン酸鉄リチウムを含む、請求項10に記載の方法。
- 前記光源が450〜500ナノメートルの波長で青色光を放射する、請求項1に記載の方法。
- 前記光源が470〜480ナノメートルの波長で青色光を放射する、請求項12に記載の方法。
- 前記光源が約2,000〜3,000ルクスの光を放射する、請求項13に記載の方法。
- 前記光源が475〜525ナノメートルの波長で緑色光を放射する、請求項1に記載の方法。
- 前記光源が490〜510ナノメートルの波長で緑色光を放射する、請求項15に記載の方法。
- 前記光源が約300〜400ルクスの光を放射する、請求項16に記載の方法。
- 前記光源が1つ又は2つ以上の発光ダイオードを含む、請求項1に記載の方法。
- 前記眼科用レンズが1本又は2本以上の光パイプを含む、請求項18に記載の方法。
- 前記1本又は2本以上の光パイプが光ファイバー経路を含む、請求項19に記載の方法。
- 前記眼科用レンズの中央5mmは、前記エネルギー源及び光源のいずれの不透明部分によっても妨害されていない、請求項1に記載の方法。
- 前記光源は、装着者の目の角膜に向かって照明を向けるように位置づけられる、請求項1に記載の方法。
- 前記第1の成形部分に近接して、プロセッサおよびメモリストレージデバイスを定置することを更に含む、請求項1に記載の方法。
- 前記プロセッサは、前記光源の動作のためのスケジュールを決定することができる、請求項23に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161439535P | 2011-02-04 | 2011-02-04 | |
US61/439,535 | 2011-02-04 | ||
US13/362,275 US9446262B2 (en) | 2011-02-04 | 2012-01-31 | Apparatus and method for formation of an energized ophthalmic device for light therapy |
US13/362,275 | 2012-01-31 | ||
PCT/US2012/023663 WO2012106535A1 (en) | 2011-02-04 | 2012-02-02 | Apparatus and method for formation of an energized ophthalmic device for light therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014512555A JP2014512555A (ja) | 2014-05-22 |
JP6316591B2 true JP6316591B2 (ja) | 2018-04-25 |
Family
ID=46600108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013552634A Active JP6316591B2 (ja) | 2011-02-04 | 2012-02-02 | 光線療法用のエネルギー印加された眼科用装置を形成するための装置及び方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9446262B2 (ja) |
EP (1) | EP2670483B1 (ja) |
JP (1) | JP6316591B2 (ja) |
KR (1) | KR101932403B1 (ja) |
CN (1) | CN103338816B (ja) |
AR (1) | AR085137A1 (ja) |
CA (1) | CA2826242A1 (ja) |
IL (1) | IL227537A0 (ja) |
RU (1) | RU2561984C2 (ja) |
SG (1) | SG191984A1 (ja) |
TW (1) | TWI603727B (ja) |
WO (1) | WO2012106535A1 (ja) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8348424B2 (en) * | 2008-09-30 | 2013-01-08 | Johnson & Johnson Vision Care, Inc. | Variable focus ophthalmic device |
WO2013158418A1 (en) * | 2012-04-19 | 2013-10-24 | Legerton Jerome A | Eye-wear borne electromagnetic radiation refractive therapy |
US9146407B2 (en) * | 2012-08-10 | 2015-09-29 | Mitsui Chemicals, Inc. | Fail-safe electro-active lenses and methodology for choosing optical materials for fail-safe electro-active lenses |
US9176332B1 (en) * | 2012-10-24 | 2015-11-03 | Google Inc. | Contact lens and method of manufacture to improve sensor sensitivity |
US8874182B2 (en) * | 2013-01-15 | 2014-10-28 | Google Inc. | Encapsulated electronics |
US9289954B2 (en) | 2013-01-17 | 2016-03-22 | Verily Life Sciences Llc | Method of ring-shaped structure placement in an eye-mountable device |
US9636016B1 (en) * | 2013-01-25 | 2017-05-02 | Verily Life Sciences Llc | Eye-mountable devices and methods for accurately placing a flexible ring containing electronics in eye-mountable devices |
US20140272176A1 (en) * | 2013-03-15 | 2014-09-18 | Johnson & Johnson Vision Care, Inc. | Method and apparatus for spatially locating lens components on a lens precursor |
US9470395B2 (en) | 2013-03-15 | 2016-10-18 | Abl Ip Holding Llc | Optic for a light source |
US9465236B2 (en) * | 2013-03-15 | 2016-10-11 | Johnson & Johnson Vision Care, Inc. | Ophthalmic devices incorporating photonic elements |
US9289623B2 (en) * | 2013-03-15 | 2016-03-22 | Johnson & Johnson Vision Care, Inc. | Method and device for monitoring and treatment of seasonal affective disorder |
US9389433B2 (en) * | 2013-03-15 | 2016-07-12 | Johnson Johnson Vision Care, Inc. | Methods and apparatus to form ophthalmic devices incorporating photonic elements |
US9316848B2 (en) * | 2013-03-15 | 2016-04-19 | Johnson & Johnson Vision Care, Inc. | Ophthalmic devices with stabilization features |
US9873233B2 (en) * | 2013-03-15 | 2018-01-23 | Johnson & Johnson Vision Care, Inc. | Ophthalmic lens viewing sets for three-dimensional perception of stereoscopic media |
US9977256B2 (en) * | 2013-05-30 | 2018-05-22 | Johnson & Johnson Vision Care, Inc. | Methods for manufacturing and programming an energizable ophthalmic lens with a programmable media insert |
US9217881B2 (en) * | 2013-05-30 | 2015-12-22 | Johnson & Johnson Vision Care, Inc. | Apparatus for programming an energizable ophthalmic lens with a programmable media insert |
CN108378984B (zh) | 2013-06-25 | 2020-06-26 | Tec晶体有限责任公司 | 用于眼睛的光线疗法的装置 |
US8833934B1 (en) | 2013-06-28 | 2014-09-16 | Google Inc. | Devices and methods for a contact lens with an outward facing light source |
US9668646B2 (en) * | 2013-06-28 | 2017-06-06 | Verily Life Sciences Llc | Devices and methods for a contact lens with an inward facing light source |
JP6240997B2 (ja) * | 2013-08-13 | 2017-12-06 | 国立研究開発法人農業・食品産業技術総合研究機構 | ガラス化後のハイドロゲル膜の製造方法、ハイドロゲル材料の製造方法、ガラス化後のハイドロゲル膜、ガラス化後のハイドロゲル膜の乾燥体および細胞シート |
US9801560B2 (en) | 2013-08-27 | 2017-10-31 | Johnson & Johnson Vision Care, Inc. | Ophthalmic lens with a neural frequency detection system |
US9185486B2 (en) * | 2013-08-27 | 2015-11-10 | Johnson & Johnson Vision Care, Inc. | Ophthalmic lens with micro-acoustic elements |
US20150065824A1 (en) * | 2013-08-28 | 2015-03-05 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form ophthalmic devices incorporating fluorescence detectors |
US9170646B2 (en) * | 2013-09-04 | 2015-10-27 | Johnson & Johnson Vision Care, Inc. | Ophthalmic lens system capable of interfacing with an external device |
US9225375B2 (en) | 2013-09-23 | 2015-12-29 | Johnson & Johnson Vision Care, Inc. | Ophthalmic lens system capable of wireless communication with multiple external devices |
US9731437B2 (en) | 2013-11-22 | 2017-08-15 | Johnson & Johnson Vision Care, Inc. | Method of manufacturing hydrogel ophthalmic devices with electronic elements |
US10817051B2 (en) * | 2014-03-13 | 2020-10-27 | Julian Michael Urbach | Electronic contact lenses and an image system comprising the same |
US9907498B2 (en) * | 2014-09-04 | 2018-03-06 | Verily Life Sciences Llc | Channel formation |
WO2016106210A1 (en) * | 2014-12-22 | 2016-06-30 | TECLens, LLC | Improved uv application device |
US9798147B1 (en) | 2015-05-28 | 2017-10-24 | Verily Life Sciences Llc | Near-eye display with phase map |
US9810910B1 (en) | 2015-05-28 | 2017-11-07 | Verily Life Sciences Llc | Contact lens with phase map display |
US9985334B2 (en) * | 2015-10-21 | 2018-05-29 | Johnson & Johnson Vision Care, Inc. | Antenna mandrel with multiple antennas |
US10953240B2 (en) | 2015-12-09 | 2021-03-23 | Alvalux Medical | Ocular devices |
US10092177B1 (en) * | 2015-12-30 | 2018-10-09 | Verily Life Sciences Llc | Device, system and method for image display with a programmable phase map |
US9977258B2 (en) * | 2016-04-14 | 2018-05-22 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to enhance oxygen concentrations for ophthalmic devices |
US9964780B2 (en) * | 2016-04-14 | 2018-05-08 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to enhance oxygen concentrations for advanced ophthalmic devices |
RU2019104738A (ru) * | 2016-07-21 | 2020-08-24 | Джонсон Энд Джонсон Вижн Кэа, Инк. | Биомедицинское устройство, включающее в себя оболочку |
WO2018088980A2 (en) * | 2016-07-28 | 2018-05-17 | Akyol Korkud Attila | A night vision contact lens |
WO2018060069A1 (en) | 2016-09-29 | 2018-04-05 | Koninklijke Philips N.V. | A wireless sensor system, for use in a phototherapy system, capable of harvesting energy |
WO2018075229A1 (en) | 2016-10-03 | 2018-04-26 | California Institute Of Technology | Radioluminescent phototherapy eye device |
CN107239050A (zh) * | 2017-01-23 | 2017-10-10 | 谢圣超 | 一种基于互联网的眼科用手持式交联治疗控制系统 |
CN107894501A (zh) * | 2017-11-06 | 2018-04-10 | 深圳先进技术研究院 | 一种角膜接触镜试剂盒及其应用 |
EP3746178A4 (en) * | 2018-01-31 | 2022-03-09 | California Institute of Technology | ADJUSTABLE EYE PHOTOTHERAPY |
WO2020014074A1 (en) | 2018-07-07 | 2020-01-16 | Acucela Inc. | Device to prevent retinal hypoxia |
EP3830636A4 (en) | 2018-07-30 | 2022-04-13 | Acucela Inc. | ELECTRONIC CONTACT LENS OPTICAL DESIGNS TO SLOW THE PROGRESSION OF MYOPIA |
US11707595B2 (en) | 2018-09-25 | 2023-07-25 | Koninklijke Philips N.V. | Controlling light exposure for circadian phase management |
IT201900008739A1 (it) * | 2019-06-12 | 2020-12-12 | Dandrea Pierdomenico Ditta Individuale | Dispositivo di induzione elettromagnetica per trattamenti oftalmici |
CN114502120A (zh) | 2019-07-31 | 2022-05-13 | 奥克塞拉有限公司 | 用于将图像投射到视网膜上的设备 |
US11733545B2 (en) | 2019-09-16 | 2023-08-22 | Acucela Inc. | Assembly process for an electronic soft contact lens designed to inhibit progression of myopia |
CN114929333A (zh) * | 2019-10-21 | 2022-08-19 | 荧康医疗创新私人有限公司 | 用于光疗的方法和装置 |
US11777340B2 (en) | 2020-02-21 | 2023-10-03 | Acucela Inc. | Charging case for electronic contact lens |
WO2021231684A1 (en) | 2020-05-13 | 2021-11-18 | Acucela Inc. | Electro-switchable spectacles for myopia treatment |
CA3179939A1 (en) | 2020-06-08 | 2021-12-16 | Acucela Inc. | Lens with asymmetric projection to treat astigmatism |
AU2021289593A1 (en) | 2020-06-08 | 2022-10-20 | Acucela Inc. | Projection of defocused images on the peripheral retina to treat refractive error |
KR20230020391A (ko) | 2020-06-08 | 2023-02-10 | 어큐셀라 인코포레이티드 | 누진 굴절 이상을 치료하기 위해 주변 디포커스를 이용하는 디바이스 상의 스틱 |
US11281022B2 (en) | 2020-06-10 | 2022-03-22 | Acucela Inc. | Apparatus and methods for the treatment of refractive error using active stimulation |
US11209672B1 (en) | 2021-04-06 | 2021-12-28 | Acucela Inc. | Supporting pillars for encapsulating a flexible PCB within a soft hydrogel contact lens |
US11366341B1 (en) | 2021-05-04 | 2022-06-21 | Acucela Inc. | Electronic case for electronic spectacles |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1309545A (en) | 1969-04-02 | 1973-03-14 | Nat Res Dev | Therapetic device |
CN1028488C (zh) | 1992-04-01 | 1995-05-24 | 中国人民解放军成都军区总医院 | 偏头痛防治镜 |
US7108414B2 (en) * | 1995-06-27 | 2006-09-19 | Solid State Opto Limited | Light emitting panel assemblies |
US20070285385A1 (en) | 1998-11-02 | 2007-12-13 | E Ink Corporation | Broadcast system for electronic ink signs |
TW541186B (en) * | 2000-09-08 | 2003-07-11 | Koninkl Philips Electronics Nv | Method for controlling the alertness of a human subject and a light source for use in this method |
CN2512449Y (zh) * | 2001-12-30 | 2002-09-25 | 沈国林 | 光谱安眠舒神仪 |
JP4630864B2 (ja) * | 2003-05-01 | 2011-02-09 | フリンダーズ パートナーズ ピーティワイ リミテッド | 光刺激を与えるための装置 |
DE102006005652A1 (de) | 2006-02-08 | 2007-09-06 | Spahl, Robert, Dr.-Ing. | Kontaktlinsenanzeige |
US8446341B2 (en) | 2007-03-07 | 2013-05-21 | University Of Washington | Contact lens with integrated light-emitting component |
CN201156832Y (zh) * | 2007-11-08 | 2008-11-26 | 复旦大学 | 抑郁症辅助治疗的led照明灯具 |
CN201170506Y (zh) * | 2007-12-04 | 2008-12-24 | 杨理荣 | 抗抑郁催眠灯 |
CN201213975Y (zh) * | 2008-05-28 | 2009-04-01 | 孙介光 | 舌穴脑病治疗仪 |
US9296158B2 (en) | 2008-09-22 | 2016-03-29 | Johnson & Johnson Vision Care, Inc. | Binder of energized components in an ophthalmic lens |
US20100078837A1 (en) * | 2008-09-29 | 2010-04-01 | Pugh Randall B | Apparatus and method for formation of an energized ophthalmic device |
US9427920B2 (en) | 2008-09-30 | 2016-08-30 | Johnson & Johnson Vision Care, Inc. | Energized media for an ophthalmic device |
US9375885B2 (en) * | 2008-10-31 | 2016-06-28 | Johnson & Johnson Vision Care, Inc. | Processor controlled ophthalmic device |
US9375886B2 (en) | 2008-10-31 | 2016-06-28 | Johnson & Johnson Vision Care Inc. | Ophthalmic device with embedded microcontroller |
CN101732804B (zh) * | 2008-11-20 | 2011-06-15 | 北京大学 | 昼夜节律紊乱治疗仪及其制作方法 |
-
2012
- 2012-01-31 US US13/362,275 patent/US9446262B2/en active Active
- 2012-02-02 JP JP2013552634A patent/JP6316591B2/ja active Active
- 2012-02-02 RU RU2013140680/05A patent/RU2561984C2/ru not_active IP Right Cessation
- 2012-02-02 WO PCT/US2012/023663 patent/WO2012106535A1/en active Application Filing
- 2012-02-02 CA CA2826242A patent/CA2826242A1/en not_active Abandoned
- 2012-02-02 CN CN201280007438.1A patent/CN103338816B/zh not_active Expired - Fee Related
- 2012-02-02 SG SG2013054168A patent/SG191984A1/en unknown
- 2012-02-02 EP EP12711988.1A patent/EP2670483B1/en active Active
- 2012-02-02 KR KR1020137023285A patent/KR101932403B1/ko active IP Right Grant
- 2012-02-03 AR ARP120100363A patent/AR085137A1/es unknown
- 2012-02-03 TW TW101103456A patent/TWI603727B/zh not_active IP Right Cessation
-
2013
- 2013-07-18 IL IL227537A patent/IL227537A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2826242A1 (en) | 2012-08-09 |
CN103338816A (zh) | 2013-10-02 |
IL227537A0 (en) | 2013-09-30 |
RU2561984C2 (ru) | 2015-09-10 |
EP2670483B1 (en) | 2020-06-03 |
US20120199995A1 (en) | 2012-08-09 |
JP2014512555A (ja) | 2014-05-22 |
AR085137A1 (es) | 2013-09-11 |
CN103338816B (zh) | 2016-10-26 |
TW201236661A (en) | 2012-09-16 |
US9446262B2 (en) | 2016-09-20 |
TWI603727B (zh) | 2017-11-01 |
EP2670483A1 (en) | 2013-12-11 |
KR101932403B1 (ko) | 2018-12-27 |
KR20140044303A (ko) | 2014-04-14 |
WO2012106535A1 (en) | 2012-08-09 |
SG191984A1 (en) | 2013-08-30 |
RU2013140680A (ru) | 2015-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6316591B2 (ja) | 光線療法用のエネルギー印加された眼科用装置を形成するための装置及び方法 | |
JP5788322B2 (ja) | エネルギー印加された眼科用装置の形成方法 | |
JP5607635B2 (ja) | 眼科用レンズ内のエネルギー印加された構成要素の結合剤 | |
JP6174041B2 (ja) | 液晶エレメントを含む可変視覚眼用デバイス | |
US9180636B2 (en) | Variable focus ophthalmic device | |
RU2505406C2 (ru) | Субстрат с источником энергии для офтальмологического устройства | |
JP2019066865A (ja) | 積層一体型構成要素を含むエネルギー印加された眼用レンズ | |
RU2508200C2 (ru) | Способ закрепления компонентов с энергопитанием в офтальмологической линзе | |
JP6312605B2 (ja) | 眼科用装置向け積層型統合コンポーネント媒体挿入物 | |
AU2012212137A1 (en) | Apparatus and method for formation of an energized ophthalmic device for light therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150106 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151022 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151027 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160226 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160915 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160928 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20161021 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170816 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171016 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171110 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180328 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6316591 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |